KRAS and neoplasm: Therefore, in this study, using specific antibodies we have investigated the expression levels of wtEGFR, EGFRvIII, phosphorylated EGFR and all seven EGFR ligands in tumour specimens from 60 mCRC patients with KRAS wild-type status treated with cetuximab and their associations with clinicopathological parameters, PFS and OS.